Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Account Payables (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Change in Account Payables data on record, last reported at $1.1 million in Q4 2025.

  • For Q4 2025, Change in Account Payables rose 215.57% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $481000.0, up 119.43%, while the annual FY2025 figure was $481000.0, 119.43% up from the prior year.
  • Change in Account Payables reached $1.1 million in Q4 2025 per FHTX's latest filing, up from -$110000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.7 million in Q1 2023 and bottomed at -$1.4 million in Q2 2022.
  • Average Change in Account Payables over 5 years is $30050.0, with a median of -$65500.0 recorded in 2021.
  • The widest YoY moves for Change in Account Payables: up 847.62% in 2022, down 390.1% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at -$21000.0 in 2021, then surged by 847.62% to $157000.0 in 2022, then plummeted by 250.32% to -$236000.0 in 2023, then surged by 241.53% to $334000.0 in 2024, then soared by 215.57% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $1.1 million in Q4 2025, -$110000.0 in Q3 2025, and -$747000.0 in Q2 2025.